comprehensive -WSS

comprehensive

author：focus 2025-09-30 15:17:04 - browse：67

Pascal Soriot 2019 — Pascal Soriot has served as CEO of AstraZeneca since 2012. Win McNamee/Getty Images

CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest of the decade, seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030.

Hitting such a target would depend on the launch of 20 new medicines and continued growth of its cancer and rare disease therapies, as well as other drugs. It would also require outpacing the targets laid out by AstraZeneca’s large pharma peers.

But at an investor day here at the company’s shiny new Discovery Centre, CEO Pascal Soriot opened his presentation by bringing up the goal set by the company a decade ago — $45 billion in revenue by 2023. The company faced some declines early in that period, but after surging in the past few years, it hit that target, bringing in $45.8 billion last year. Its recent growth has also propelled the company’s share price.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Infectious disease expert Jeanne Marrazzo assumes Fauci role

WSS

Wildfire pollution widens asthma inequities on Long Island

Why Charlie Gard's case is so disturbing to Americans

Why age limits for politicians are a terrible idea

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Scientists inch closer to single

Bristol 'take

Wikipedia

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

After affirmative action ruling, medical educators look to 'holistic review'

5 important ways Henrietta Lacks changed medical science

Hepatitis C has a cure — but many Americans still lack access to it

Liquid biopsy for lung cancer is launched by Delfi

In Memoriam: Notable people who died in 2023

NIH launches clinical trials and new research office for long Covid

Anesthesiologist group: stop taking Ozempic before surgery

FDA panel signals lack of confidence in Amgen cancer drug data

23andMe had bad news about my health. I wish a person had delivered it

Vertex non

focus

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

What the airline industry can learn from medicine

Physician groups backed by private equity giant lobby on mergers

Lawsuit alleges UnitedHealth Group unit illegally denied claims

NIH launches clinical trials and new research office for long Covid

No plane should take off without an EpiPen onboard

focus

Wikipedia

focus

knowledge